These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28217196)

  • 41. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
    Bell SC; Mainz JG; MacGregor G; Madge S; Macey J; Fridman M; Suthoff ED; Narayanan S; Kinnman N
    BMC Pulm Med; 2019 Aug; 19(1):146. PubMed ID: 31409396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
    Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
    Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.
    Bratcher PE; Rowe SM; Reeves G; Roberts T; Szul T; Harris WT; Tirouvanziam R; Gaggar A
    J Cyst Fibros; 2016 Jan; 15(1):67-73. PubMed ID: 25769931
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
    J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.
    Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F
    J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute administration of ivacaftor to people with cystic fibrosis and a
    Adam RJ; Hisert KB; Dodd JD; Grogan B; Launspach JL; Barnes JK; Gallagher CG; Sieren JP; Gross TJ; Fischer AJ; Cavanaugh JE; Hoffman EA; Singh PK; Welsh MJ; McKone EF; Stoltz DA
    JCI Insight; 2016 Apr; 1(4):e86183. PubMed ID: 27158673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
    N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.
    Dilokthornsakul P; Hansen RN; Campbell JD
    Eur Respir J; 2016 Jun; 47(6):1697-705. PubMed ID: 27126691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
    Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
    J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D).
    Polenakovik HM; Sanville B
    J Cyst Fibros; 2013 Sep; 12(5):530-1. PubMed ID: 23313410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
    Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
    Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up.
    Fila L; Valentova Bartakova L; Grandcourtova A; Marel M; Drnek R; Bilkova A; Macek M; Drevinek P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Jun; 160(2):276-9. PubMed ID: 27226150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis.
    Blondeau K; Dupont LJ; Mertens V; Verleden G; Malfroot A; Vandenplas Y; Hauser B; Sifrim D
    Gut; 2008 Aug; 57(8):1049-55. PubMed ID: 18372497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
    J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.